Skip to main content
Clinical Trials/NCT04099940
NCT04099940
Recruiting
Not Applicable

Virtual Reality Avatar Therapy for People Hearing Voices

Psychiatric University Hospital, Zurich1 site in 1 country100 target enrollmentJuly 1, 2021

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Psychosis
Sponsor
Psychiatric University Hospital, Zurich
Enrollment
100
Locations
1
Primary Endpoint
Psychopathological Assessment
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

Hearing voices is probably the worst form of acoustic hallucinations; which can be experienced as severely disturbing and is influenced by diverse factors including the ability of the individual to influence and control the hallucinatory experience itself. In recent years virtual reality has become a treatment option. In the so-called AVATAR Therapy, patients with schizophrenia and acoustic hallucinations design a visual and auditory recreation (avatar) of the entity to which they attribute their hallucinations. Working with a therapist over the course of several sessions, participants change the avatar from controlling to benevolent. Avatar Therapy involves similar processes to learning and cognitive restructuring, comparable to other psychotherapeutic interventions. The investigators plan to conduct an interventional study using a cross-over design, to compare the feasibility and efficacy of virtual reality avatar therapy for patients with acoustic hallucinations (independent of psychiatric diagnosis) with a cognitive behavioural group therapy aimed to improve social competence.

Registry
clinicaltrials.gov
Start Date
July 1, 2021
End Date
December 31, 2025
Last Updated
2 years ago
Study Type
Interventional
Study Design
Crossover
Sex
All

Investigators

Sponsor
Psychiatric University Hospital, Zurich
Responsible Party
Principal Investigator
Principal Investigator

Stephan T. Egger

Senior Psychiatrists

Psychiatric University Hospital, Zurich

Eligibility Criteria

Inclusion Criteria

  • Consistent acoustic hallucinations, with the presence of voices for at least two months.
  • Participants are competent to give informed consent, as determined by the referring physician or psychiatrist.
  • German language proficiency as a native speaker or level B1 Common European Framework of Reference for Languages (CEFRL)

Exclusion Criteria

  • Current neurological disorder.
  • Current substance use or withdrawal.
  • Concomitant group psychotherapeutic intervention.

Outcomes

Primary Outcomes

Psychopathological Assessment

Time Frame: Change: Baseline, 3, 6 weeks, 6 and 12 months]

Symptom Questionnaire

Secondary Outcomes

  • Insecurity- Self-confidence(Change: Baseline, 3, 6 weeks, 6 and 12 months])
  • Psychotic Symptoms(Change: Baseline, 3, 6 weeks, 6 and 12 months])

Study Sites (1)

Loading locations...

Similar Trials